Global Respiratory Drugs Market 2016-2020 - Promising Late-Stage Pipeline Molecules Drives the Market - Research and Markets

May 25, 2016, 05:10 ET from Research and Markets

DUBLIN, May 25, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Respiratory Drugs Market 2016-2020" report to their offering. 

     (Logo: )

The global respiratory drugs market to grow at a CAGR of 6.48% during the period 2016-2020. 

Global Respiratory Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of prescription and over-the-counter (OTC) drugs used to treat respiratory diseases. 

A noteworthy trend in the respiratory drugs market is the use of biologics. In recent times, biologics are increasingly becoming the preferred choice to treat respiratory diseases, and they act by blocking the interleukins and reducing inflammation caused in the respiratory tract. For example, Xolair (omalizumab) by Genentech and Novartis is the only approved biologic drug for the treatment of asthma. 

According to the report, a key growth driver is the rising prevalence of respiratory diseases around the world. The CDC reported that as of May 2011, about 25 million Americans, which isone in 12 individuals in the US, had asthma. In 2015, the National Institute of Allergy and Infectious Diseases (NIAID) reported that globally about 250 million people had asthma. According to the WHO factsheet 2016, approximately 8% of the Swiss population, four million Germans, three million Japanese, and 15-20 million Indians are estimated to have asthma. Many respiratory occur due to genetic factors and lifestyle factors such as vehicular pollution and exposure to animals or pets. Rising prevalence of respiratory diseases results in more people seeking treatment, increasing the intake of medicines, thereby contributing to the respiratory drugs market. 

Further, the report states that a major challenge with the potential to hamper market growth is the unknown etiology of respiratory problems like asthma and idiopathic pulmonary fibrosis. 

Key vendors 

- AstraZeneca 
- Boehringer Ingelheim 
- F.Hoffman La-Roche 
- GlaxoSmithKline 
- Merck 
- Novartis 

Key Topics Covered: 

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Overview: Respiratory diseases

Part 06: Pipeline analysis

Part 07: Market landscape

Part 08: Market segmentation by class of drugs

Part 09: Market segmentation by disease

Part 10: Geographical segmentation

Part 11: Market drivers

Part 12: Impact of drivers

Part 13: Market challenges

Part 14: Impact of drivers and challenges

Part 15: Market trends

Part 16: Vendor landscape

Part 17: Appendix 

For more information visit

Media Contact:
Laura Wood, Senior Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets